This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
“New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK's regulatory agency on this vital project."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
“New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK's regulatory agency on this vital project."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
“New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK's regulatory agency on this vital project."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
“New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK's regulatory agency on this vital project."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
“New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK's regulatory agency on this vital project."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
